[Skip navigation] FDA:  Office of Planning

Report on PDUFA Goals: Original New Product Applications

Goal: Review and act upon complete NDAs and BLAs

The table below summarizes the annually decreasing review-time goals for original New Drug Applications (NDAs) and BLAs under PDUFA II. Over the five-year period, the goal of reviewing 90 percent of priority applications in six months remains constant. For standard applications, the review-time goals drop over the five-year period. For applications filed in FY 98, the goal was to review 90 percent in 12 months; for FY 02 applications, the goal is to review 90 percent in 10 months. For standard applications filed in FY 2000, the goal was to review 90 percent in 12 months and 50 percent in 10 months.

Goals

On-Time Performance by Submission Year

FY 98

FY 99

FY 00

FY 01

FY 02

Priority

6 months

90% on time

90%

90%

90%

90%

Standard

12 months

10 months

90%

90%

30%

90%

50%

90%

70%

90%

Workload

The following table shows the number of original NDAs and BLAs filed in each of the last five years. The count of FY 00 submissions assumes that all submissions received in the last two months of FY 00 are filed. When FDA files a submission, it is deemed "complete" by PDUFA definition. FDA makes a filing decision within 60 days of an original application's receipt. All calculations of PDUFA review times are made, however, from the original receipt date of the filed application.

Original submissions filed (Priority/Standard):

 

FY 96

FY 97

FY 98

FY 99

FY 004

  • NDAs

106

117 (25/92)

109 (30/79)

121 (30/91)

121 (27/94)

  • BLAs

9

16 (3/13)

12 (8/4)

6 (1/5)

13 (4/9)

  • PDUFA Total

115

133 (28/105)

121 (38/83)

127 (31/96)

134 (31/103)

NMEs5

42 (19/23)

41 (16/25)

35 (17/18)

Performance:

FY 99 Submissions:
For FY 99 applications, FDA met the 6-month review goal for priority submissions and the 12-month goal6 for standard submissions in every case. Two standard applications submitted late in FY 99 are still pending but have not exceeded the 12-month goal . Sixty-eight percent of all standard applications and 60 percent of the NMEs and BLAs were reviewed and acted upon within 10 months, exceeding the 30 percent review goal in both cases.

FY 99 Submissions

Reviewed and acted upon

Number on time

Percent on time

Priority

6 month goal

All Applications

31

31

100

NMEs & BLAs

17

17

100

Standard

12 month goal

All Applications

94*

94

100*

NMEs & BLAs

30

30

100

10 month goal

All Applications

94

64

68

NMEs & BLAs

30

18

60

*Two standard submissions still pending but not late.

FY 00 Submissions:

While it is too early to report meaningful review performance statistics for standard applications submitted in FY 00, all priority applications that have been reviewed have met the 6 month review goal.

FY 00 Submissions

Reviewed and acted upon

Number on time

Percent on time

Priority

6 month goal

All Applications

18

18

100

NMEs & BLAs

9

9

100

Standard

12 month goal

All Applications

Too early to report meaningful review performance statistics. Sixteen standard applications have been reviewed and acted upon, all within 10 months.

NMEs & BLAs

10 month goal

All Applications

NMEs & BLAs

 

Next Page | Table of Contents | Previous Page



FDA Home Page
| Search | A-Z Index | Site Map | Contact FDA

FDA/Office of Planning
Web page created by cm 2001-MAR-01.